Associated tags: Therapy, Disease, Genetics, Biology, Patient, Amgen, AMGN, Government, IRS, Tax, ASC, Cryptocurrency
Locations: JAPAN, ASIA, SINGAPORE, EUROPEAN UNION, UNITED STATES, NORTH AMERICA, NEW YORK, LOS ANGELES, RADNOR, PA, US, CAN, NY, RHODE ISLAND, NETHERLANDS, PENNSYLVANIA, NEW JERSEY, CA, SAN DIEGO, MIDDLE EAST, SWITZERLAND, EUROPE, AFRICA, AMERICAS, LONDON, CHICAGO, PARIS, TEL AVIV, NORFOLK, BENSALEM, WHITE PLAINS, USA, SPAIN, ALABAMA, WALTHAM, MA, ITALY, DENMARK, COPENHAGEN, ILLINOIS, ANAL, CHINA, CANADA, AUSTRALIA, BEIJING, SOUTH AMERICA, IRELAND, UNITED STATES OF AMERICA, UNITED KINGDOM, FRANCE, GERMANY, BRAZIL, ICELAND, MEXICO, UK, POMPANO BEACH, FL, PHILADELPHIA, FLORIDA, CR, BONE, NOVA, KRAS, FINLAND, CALIFORNIA, TD, OHIO
Pustulosis palmaris et plantaris,
Psoriasis,
CPU socket,
Aes,
Headache,
Diarrhea,
Amgen,
Pain,
Pediatrics,
DLQI,
Skin,
Nausea,
Vomiting,
Queen's University,
AMGN,
AAD,
Safety,
University,
FRCPC,
University of Alberta,
PASI,
Dermatology Life Quality Index,
Patient,
PST,
Scalp,
Ageing,
Abdominal pain,
Poster,
American Academy,
Pharmaceutical industry THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
Key Points:
- These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
- "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
- Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
- Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.
Retrieved on:
Thursday, February 29, 2024
THOUSAND OAKS, Calif., Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m.
Key Points:
- THOUSAND OAKS, Calif., Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m.
- Peter Griffith, executive vice president and chief financial officer at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen, will present at the conference.
- The webcast will be archived and available for replay for at least 90 days after the event.
- To provide further context, information and detail around our activities with respect to our obesity program, Amgen has established a website called "Amgen Perspectives in Obesity".
Retrieved on:
Monday, February 26, 2024
"Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen.
Key Points:
- "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen.
- "As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines."
- "Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy."
- In partnership with Columbus State Community College, Amgen is hosting an inaugural 18-month manufacturing apprenticeship at the site.
Retrieved on:
Monday, February 19, 2024
THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.
Key Points:
- THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.
- Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani, executive vice president of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen, will participate in the conference call.
- The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
- Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
THOUSAND OAKS, Calif., Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m.
Key Points:
- THOUSAND OAKS, Calif., Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m.
- Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon, executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities at Amgen, will present at the conference.
- Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
- The webcast will be archived and available for replay for at least 90 days after the event.
Retrieved on:
Thursday, February 1, 2024
THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.
Key Points:
- THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.
- The announcement will be followed by a conference call with the investment community at 4:30 p.m.
- Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
- Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
Woman,
Synaptonemal complex,
Genetic distance,
Biology,
Genome-wide association study,
Genetics,
Meiosis,
Risk,
Pregnancy,
Chromosome,
Genome,
AMGN Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
Key Points:
- Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
- A low-frequency missense variant in the SYCE2 gene was found to increase the risk of pregnancy loss by 22%.
- The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
- The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.
Woman,
Synaptonemal complex,
Genetic distance,
Biology,
Genome-wide association study,
Genetics,
Meiosis,
Risk,
Pregnancy,
Chromosome,
Genome,
AMGN Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
Key Points:
- Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
- A low-frequency missense variant in the SYCE2 gene was found to increase the risk of pregnancy loss by 22%.
- The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
- The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.
Pancreatic cancer,
Research,
Biology,
Prostate cancer,
Cancer,
Cytokine release syndrome,
CRS,
AML,
Population Reference Bureau,
Audit committee,
AMGN,
NK,
Neoplasm,
ADC,
Acute myeloid leukemia,
Paracetamol,
PMR,
NKG2D,
NSCLC,
Disease,
Safety,
Conditional sentence,
Brain,
Lung cancer,
Breast,
PALM,
Cytarabine,
Senior,
Prevalence,
Genetics,
Nonsteroidal anti-inflammatory drug,
Drug discovery,
Graft-versus-host disease,
Ruxolitinib,
TSX,
Therapy,
Kidney cancer,
Ageing,
Patient,
Stomach,
Complete Response Letter,
Fentanyl,
Breast cancer,
Novartis,
Society,
Eli Lilly,
News,
Food,
Cancer pain,
Johnson & Johnson,
Morphine,
FDA,
Ovarian cancer,
New Drug Application,
ASH,
ONC,
Pharmaceutical industry Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
Key Points:
- Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
- The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
- According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
- The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.
Retrieved on:
Wednesday, January 3, 2024
THOUSAND OAKS, Calif., Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024.
Key Points:
- THOUSAND OAKS, Calif., Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024.
- Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference.
- The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
- Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
